The use of omalizumab for other allergic diseases has been demonstrated in small studies and case reports:
- Allergic rhinitis - effective
- Immunotherapy - adds safety to immunotherapy
- Food allergy - effectiveness shown with different formulation of anti-IgE (TNX-901) than omalizumab
- Atopic dermatitis - conflicting evidence. Serum IgE levels are typically increased in atopic dermatitis - there is often difficulty in significantly reducing extremely increased IgE levels.
- Chronic urticaria/angioedema Idiopathic, autoimmune, cholinergic, cold induced. Approximately 50% of patients with chronic urticaria have an autoimmune component. Case reports show promise but there is no conclusive evidence.
- Nasal polyposis/sinusitis - improvement of edema
- Eosinophilic gastrointestinal diseases - decreased serum eosinophil counts and improved symptoms
- Drug allergy - one case report of insulin allergy
Anti-IgE therapy: Clinical utility beyond asthma. Thomas B. Casale, Jeffrey Stokes. Volume 123, Issue 4, Pages 770-771.e1 (April 2009).
Single-dose omalizumab (300mg) in patients with H1-antihistamine–refractory chronic idiopathic urticaria leads to improvement within 1-2 weeks. JACI, 2011.
Single dose of omalizumab (one 300 mg injection) relieves chronic idiopathic urticaria refractory to H1-antihistamines. Medscape, 2011.